The Natural History and Prognostic Factors of Compensated Cirrhosis.

计划入组 166 人 · 首次发布于 2017 年 5 月 9 日

Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.

计划入组 180 人 · 首次发布于 2024 年 2 月 20 日

Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis

计划入组 1,200 人 · 首次发布于 2005 年 9 月 19 日

Velpatasvir(Epclusa, Vosevi)

C₄₉H₅₄N₈O₈

siRNA therapy (decompensated cirrhosis)

Liver cirrhosis(Rege Nephro)

FDA Grants Premarket Approval to HepQuant SHUNT Liver Diagnostic Test for Compensated Cirrhosis

Akero Therapeutics Doses First Patient in Phase 3 SYNCHRONY Outcomes Trial for MASH Cirrhosis

Akero's Efruxifermin Shows Promise in Reversing Cirrhosis Due to MASH in Phase 2b Trial